Hottub News

APEX Part B: Zumilokibart Achieves Primary Endpoint in Atopic Dermatitis

2 reports from 2 outlets in 1 language · first reported · updated · JSON

Healthatopic dermatitisAbbVie

Reports

  1. APEX Part B: Zumilokibart Achieves Primary Endpoint in Atopic Dermatitishcplive.com · en ·
  2. AbbVie Highlights Positive Results from the Phase 2 APEX Part B Study of Zumilokibart in Moderate to Severe Atopic Dermatitis, as a Late Breaker at EADV 2026prnewswire.com · en ·

More in Health

  1. After Covid: Life expectancy has almost recovered50 outlets
  2. Doctors warn about the risks energy drinks pose to kids. What families need to know74 outlets
  3. Cat food investigation finds heavy metals, pesticides and plastic chemicals37 outlets
  4. Democratic Republic of Congo: More than 4,000 people in the DR Congo have died from Ebola65 outlets
  5. Plague in Russia? Woman died, 200 people in quarantine23 outlets
  6. Synthetic bee silk set to take sting out of wounds43 outlets